Invesco
IKT icon

Invesco’s Inhibikase Therapeutics IKT Stock Holding History

Invesco’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126K Buy
62,103
+27,746
+81% +$49.7K ﹤0.01% 3703
2026
Q1 		$57.7K Buy
34,357
+2,095
+6% +$3.72K ﹤0.01% 3683
2025
Q4 		$66.1K Sell
32,262
-772
-2% -$1.23K ﹤0.01% 3677
2025
Q3 		$53.5K Buy
33,034
+2,322
+8% +$4.02K ﹤0.01% 3744
2025
Q2 		$59.9K Buy
+30,712
New +$60.1K ﹤0.01% 3710

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco's IKT Position: Q2 2026 in Review

Invesco increased its Inhibikase Therapeutics (IKT) stake by 81% in Q2 2026, buying an estimated $49.7K and bringing the position to 62,103 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #3703.

Invesco first reported a position in IKT in Q2 2025 and has held it in 5 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Invesco held 62,103 shares of Inhibikase Therapeutics worth $126K as of Q2 2026.
  • Invesco bought 27,746 Inhibikase Therapeutics shares in Q2 2026, an estimated $49.7K.
  • Inhibikase Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3703 holding.
  • Invesco first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.